
- XV Eurasian Hematology-Oncology Congress - EHOC 2024
- XIV Eurasian Hematology-Oncology Congress - EHOC 2023
- 8th Eurasian Hematology Oncology Summit
- XIth Eurasian Hematology-Oncology Congress - EHOC 2020
- 7th Eurasian Hematology Oncology Summit
- Xth Eurasian Hematology-Oncology Congress
- Events
Playback speed
10 seconds
Risk Stratification and Treatment of CLL: If New Drugs Available, 17p / TP53 Should Be Tested at 1st-Line and Relapse/Refractory
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Robin Foa
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Robin Foa
0 views
December 20, 2019
Comments 0
Login to view comments.
Click here to Login
Hematologic Oncology